CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

CalciMedica (CALC), a clinical-stage biopharmaceutical company focused on CRAC channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, will present at the H.C.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

CalciMedica (CALC), a clinical-stage biopharmaceutical company focused on CRAC channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026.

Management will also participate in 1x1 investor meetings during the event.

Key Terms

crac channel

1 terms

crac channel technical

"developing novel calcium release-activated calcium (CRAC) channel inhibition therapies"

A CRAC channel is a specific type of protein pore in cell membranes that opens to let calcium enter cells after internal calcium stores are depleted, helping trigger processes like immune cell activation and secretion. Investors pay attention because drugs or diagnostics that block or modulate these channels can change how the immune system, inflammation, allergy, or certain cancers behave, so breakthroughs or setbacks in CRAC-targeting therapies can affect company value much like a new valve changing flow through a pipe.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/08/2026 - 07:00 AM

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will present and participate in 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company's pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora^™, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in more than 350 patients and is being developed for pulmonary arterial hypertension and acute pancreatitis, including a planned Phase 1b proof-of-concept trial in PAH and a planned Phase 2b trial in acute pancreatitis. CM5480 is being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027. For more information, please visit www.calcimedica.com.

Investor Relations Contact
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com